The Quality of Erection Questionnaire (QEQ) is a new questionnaire that was developed to assess erectile attributes in men with erectile dysfunction. The study objective is to validate the Quality of Erection Questionnaire (QEQ) through the evaluation of subject responses to the QEQ regarding the quality and hardness of erections at baseline compared to subject responses post 6 and 10 weeks dosing with Viagra (sildenafil citrate).

Condition	Intervention	Phase
Impotence	Drug: sildenafil citrate	Phase IV

Further Study Details: 

Expected Total Enrollment:  100

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Male

Criteria

Inclusion Criteria:

• Subjects must have documented clinical diagnosis of erectile dysfunction based on a screening SHI-M score of <21 and the subject fulfilling the NIH definition of erectile dysfunction
• Subjects must be either PDE-5 inhibitor naïve; i.e. have never used sildenafil, tadalafil or vardenafil, or have been previously treated with no more than six doses of a PDE-5 inhibitor (sildenafil, tadalafil, vardenafil) and must have taken their last dose no less than 4 weeks prior to the screening visit

Exclusion Criteria:

• Subjects who are currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis

Please refer to this study by ClinicalTrials.gov identifier  NCT00151463

Pfizer CT.gov Call Center      1-800-718-1021 

Australia, New South Wales
      Pfizer Investigational Site, Bondi Junction,  New South Wales,  2022,  Australia; Recruiting
      Pfizer Investigational Site, St. Leonards,  New South Wales,  2065,  Australia; Recruiting
      Pfizer Investigational Site, Darlinghurst,  New South Wales,  2010,  Australia; Completed
      Pfizer Investigational Site, Darlinghurst,  New South Wales,  2010,  Australia; Completed
Australia, Queensland
      Pfizer Investigational Site, Spring Hill,  Queensland,  4000,  Australia; Recruiting
Australia, South Australia
      Pfizer Investigational Site, Adelaide,  South Australia,  5000,  Australia; Completed
Australia, Victoria
      Pfizer Investigational Site, Malvern,  Victoria,  3144,  Australia; Recruiting
      Pfizer Investigational Site, Mentone,  Victoria,  3194,  Australia; Completed
      Pfizer Investigational Site, Clayton,  Victoria,  3168,  Australia; Completed
Australia, Western Australia
      Pfizer Investigational Site, Nedlands,  Western Australia,  6009,  Australia; Completed

Study chairs or principal investigators

Pfizer CT.gov Call Center,  Study Director,  Pfizer   

Study ID Numbers:  A1481195
Last Updated:  September 8, 2005
Record first received:  September 7, 2005
ClinicalTrials.gov Identifier:  NCT00151463
Health Authority: Australia: Human Research Ethics Committee
ClinicalTrials.gov processed this record on 2005-09-13